CST6 Rabbit Polyclonal Antibody

CAT#: TA364744

CST6 rabbit polyclonal antibody

Product Images

Immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using TA364744 (CST6 Antibody) at dilution 1/30 (Original magnification: ×200)

• 

  Immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using TA364744 (CST6 Antibody) at dilution 1/30, treated with fusion protein. (Original magnification: ×200)

• 

  Immunohistochemistry of paraffin-embedded Human liver cancer tissue using TA364744 (CST6 Antibody) at dilution 1/30 (Original magnification: ×200)

• 

  Immunohistochemistry of paraffin-embedded Human liver cancer tissue using TA364744 (CST6 Antibody) at dilution 1/30, treated with fusion protein. (Original magnification: ×200)

Specifications

Product Data

• Applications: IHC
• Recommended Dilution: IHC: 50-200
  Positive control: Human ovarian cancer
  Predicted cell location: Cytoplasm
• Reactivities: Human
• Host: Rabbit
• Isotype: IgG
• Clonality: Polyclonal
• Immunogen: Fusion protein of human CST6
• Formulation: pH7.4 PBS, 0.05% NaN3, 40% Glycerol
• Concentration: lot specific
• Purification: Antigen affinity purification
• Conjugation: Unconjugated
• Storage: Store at -20°C.
• Stability: 1 year
• Database Link:
  UniProt ID Q15828
• Background: The cystatin superfamily encompasses proteins that contain multiple cystatin-like sequences. Some of the members are active cysteine protease inhibitors, while others have lost or perhaps never acquired this inhibitory activity. There are three inhibitory families in the superfamily, including the type 1 cystatins (stefins), type 2 cystatins and the kininogens. The type 2 cystatin proteins are a class of cysteine proteinase inhibitors found in a variety of human fluids and secretions, where they appear to provide protective functions. This gene encodes a cystatin from the type 2 family, which is down-regulated in metastatic breast tumor cells as compared to primary tumor cells. Loss of expression is likely associated with the progression of a primary tumor to a metastatic phenotype.